- Home
- SNDX vs LILA Comparison
SNDX vs LILA Comparison
Compare SNDX & LILA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDX
- LILA
- Stock Information
- Founded
- SNDX 2005
- LILA 2017
- Country
- SNDX United States
- LILA Bermuda
- Employees
- SNDX N/A
- LILA N/A
- Industry
- SNDX Biotechnology: Pharmaceutical Preparations
- LILA Cable & Other Pay Television Services
- Sector
- SNDX Health Care
- LILA Telecommunications
- Exchange
- SNDX Nasdaq
- LILA Nasdaq
- Market Cap
- SNDX 1.1B
- LILA 1.1B
- IPO Year
- SNDX 2016
- LILA N/A
- Fundamental
- Price
- SNDX $10.70
- LILA $4.50
- Analyst Decision
- SNDX Strong Buy
- LILA Buy
- Analyst Count
- SNDX 11
- LILA 2
- Target Price
- SNDX $35.91
- LILA $7.90
- AVG Volume (30 Days)
- SNDX 2.3M
- LILA 646.4K
- Earning Date
- SNDX 05-05-2025
- LILA 05-07-2025
- Dividend Yield
- SNDX N/A
- LILA N/A
- EPS Growth
- SNDX N/A
- LILA N/A
- EPS
- SNDX N/A
- LILA N/A
- Revenue
- SNDX $43,722,000.00
- LILA $4,441,000,000.00
- Revenue This Year
- SNDX $263.44
- LILA $4.42
- Revenue Next Year
- SNDX $129.44
- LILA $3.59
- P/E Ratio
- SNDX N/A
- LILA N/A
- Revenue Growth
- SNDX N/A
- LILA N/A
- 52 Week Low
- SNDX $9.66
- LILA $5.12
- 52 Week High
- SNDX $25.07
- LILA $10.82
- Technical
- Relative Strength Index (RSI)
- SNDX 38.98
- LILA 26.73
- Support Level
- SNDX $9.67
- LILA $4.26
- Resistance Level
- SNDX $14.24
- LILA $5.60
- Average True Range (ATR)
- SNDX 0.93
- LILA 0.26
- MACD
- SNDX -0.26
- LILA -0.03
- Stochastic Oscillator
- SNDX 22.62
- LILA 17.75
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
About LILA Liberty Latin America Ltd.
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.